Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alder Biopharmaceuticals, an emerging antibody therapeutics company, has announced the closing of its $40 million series C financing. Delphi Ventures and TPG Biotech led the financing round.
Subscribe to our email newsletter
Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology.
Randall Schatzman, CEO and co-founder of Alder, said: “This financing will allow Alder to rapidly advance our lead antibody therapeutic ALD518 through multiple proof-of-concept trials, broaden our product pipeline, and continue to build on our proprietary antibody discovery and manufacturing technologies.”